Journal: Bioengineered

Article Title: Long non-coding RNA AC012668 suppresses non-alcoholic fatty liver disease by competing for microRNA miR-380-5p with lipoprotein-related protein LRP2

doi: 10.1080/21655979.2021.1960463

Figure Lengend Snippet: NAFLD models established to investigate changes in AC012668 expression. (a) Heat map of differentially expressed lncRNAs in NAFLD. (b) Cell viability and (c and d) apoptosis of LO2 cells treated with FFA. (e and f) Oil-Red O staining image and TG level in the liver tissues of HFD mice. (g) AC012668 expression levels in the liver tissues of HFD mice. (h) Expression of AC012668 in FFA-treated cells. *P < 0.05 vs. control; **P < 0.01 vs. control

Article Snippet: Normal human hepatocyte lines LO2 were purchased from Biowit Biotechnology Inc. (cat no. C0009).

Techniques: Expressing, Staining

Journal: Bioengineered

Article Title: Long non-coding RNA AC012668 suppresses non-alcoholic fatty liver disease by competing for microRNA miR-380-5p with lipoprotein-related protein LRP2

doi: 10.1080/21655979.2021.1960463

Figure Lengend Snippet: AC012668 suppresses TG/lipid accumulation and lipogenesis in LO2 cells. (a) AC012668 expression level in FFA-treated LO2 cells transfected with the AC012668 overexpression plasmid. (b) mRNA and (c and d) protein expression levels of SCD1, SREBP1 , and FAS in FFA-treated LO2 cells. (e) TG level and (f) Oil-Red O staining in FFA-treated LO2 cells. *P < 0.05 vs. pcDNA3.1 or AC012668.

Article Snippet: Normal human hepatocyte lines LO2 were purchased from Biowit Biotechnology Inc. (cat no. C0009).

Techniques: Expressing, Transfection, Over Expression, Plasmid Preparation, Staining

Journal: Bioengineered

Article Title: Long non-coding RNA AC012668 suppresses non-alcoholic fatty liver disease by competing for microRNA miR-380-5p with lipoprotein-related protein LRP2

doi: 10.1080/21655979.2021.1960463

Figure Lengend Snippet: miR-380-5p directly targets AC012668 . (a) Wild and mutant types of AC012668 reporters labeled with luciferase. (b) Expression levels of miR-380-5p in AC012668 -enhanced/-inhibited LO2 cells. (c) Relative luciferase activities in wild-type and mutant AC012668 groups compared with the mimic negative control group. (d) Relative enrichment of AC012668 in the biotinylated miR-380-5p group. (e) AC012668 expression levels in the liver tissues of HFD mice. (f) Expression level of miR-380-5p in LO2 cells treated with 1 mM FFA. *P < 0.05 vs. biotin-NC; **P < 0.01 vs. si-NC, vector, mimic NC, or control

Article Snippet: Normal human hepatocyte lines LO2 were purchased from Biowit Biotechnology Inc. (cat no. C0009).

Techniques: Mutagenesis, Labeling, Luciferase, Expressing, Negative Control, Plasmid Preparation

Journal: Bioengineered

Article Title: Long non-coding RNA AC012668 suppresses non-alcoholic fatty liver disease by competing for microRNA miR-380-5p with lipoprotein-related protein LRP2

doi: 10.1080/21655979.2021.1960463

Figure Lengend Snippet: miR-380-5p promotes TG/lipid accumulation and lipogenesis in LO2 cells transfected with AC012668 . (a) AC012668 expression detected using reverse transcription-quantitative polymerase chain reaction. (b) mRNA and (c and d) protein levels of SCD1, SREBP1 , and FAS . (e) TG level and (f) lipid deposition. *P < 0.05 vs. AC012668 + mimic NC; **P < 0.01 vs. vector

Article Snippet: Normal human hepatocyte lines LO2 were purchased from Biowit Biotechnology Inc. (cat no. C0009).

Techniques: Transfection, Expressing, Real-time Polymerase Chain Reaction, Plasmid Preparation

Journal: Bioengineered

Article Title: Long non-coding RNA AC012668 suppresses non-alcoholic fatty liver disease by competing for microRNA miR-380-5p with lipoprotein-related protein LRP2

doi: 10.1080/21655979.2021.1960463

Figure Lengend Snippet: LRP2 is a target of miR-380-5p . (a) Wild and mutant types of LRP2 reporters labeled with luciferase. (b) mRNA expression of LRP2 in FFA-treated LO2 cells transfected with the miR-380-5p mimic or inhibitor. (c) Relative luciferase activities in wild-type and mutant LRP2 groups compared with the mimic negative control group. (d) Relative enrichment of LRP2 in the biotinylated miR-380-5p group. (e) AC012668 expression levels in the liver tissues of HFD mice. (f) Expression level of LRP2 in FFA-treated LO2 cells. *P < 0.05 vs. biotin-NC; **P < 0.01 vs. inhibitor NC, mimic NC, or control

Article Snippet: Normal human hepatocyte lines LO2 were purchased from Biowit Biotechnology Inc. (cat no. C0009).

Techniques: Mutagenesis, Labeling, Luciferase, Expressing, Transfection, Negative Control

Journal: Bioengineered

Article Title: Long non-coding RNA AC012668 suppresses non-alcoholic fatty liver disease by competing for microRNA miR-380-5p with lipoprotein-related protein LRP2

doi: 10.1080/21655979.2021.1960463

Figure Lengend Snippet: Effects of LRP2 knockdown on TG/lipid accumulation and lipogenesis in miR-380-5p -inhibited LO2 cells. (a) miR-380-5p expression level in LO2 cells cotransfected with the miR-380-5p inhibitor and si-LRP2 . (b) mRNA and (c and d) protein levels of SCD1, SREBP1 , and FAS in the miR-380-5p inhibitor- and si-LRP2 -cotransfected cells. (e) TG level and (f) lipid deposition in the miR-380-5p inhibitor- and si-LRP2 -cotransfected cells. *P < 0.05 vs. control or miR-380-5p mimic + si-NC

Article Snippet: Normal human hepatocyte lines LO2 were purchased from Biowit Biotechnology Inc. (cat no. C0009).

Techniques: Expressing

Journal: Translational Cancer Research

Article Title: Analysis of the role of POC1A in the development and progression of hepatocellular carcinoma

doi: 10.21037/tcr-23-2398

Figure Lengend Snippet: Analysis of the expression of POC1A in various classifications of HCC patients, as well as in HCC and liver cancer cell lines. (A) Comparison of POC1A between cancer tissue samples and normal tissue samples. (B) Comparison of the expression of POC1A in different genders. (C) Comparison of the expression of POC1A in different age groups. (D) The expression levels of POC1A were all higher in the Caucasian, African-American, and Asian HCC patients than the normal patients. The expression of POC1A was significantly higher in LIHC tissue samples from Asian patients than LIHC tissue samples from Caucasian patients. (E) The expression of POC1A in individual cancer stages. (F) The expression of POC1A in different transistor grades. (G) The expression of POC1A in tumor (T) stage. (H) The expression of POC1A in node (N) stage. (I) The expression of POC1A in metastasis (M) stage. (J) Analysis of POC1A expression in normal liver tissue and cancer tissue samples from patients with hepatocellular carcinoma using immunohistochemical methods in the Human Protein Atlas database. Liver sample: https://www.proteinatlas.org/ENSG00000164087-POC1A/tissue/liver#img , hepatocellular samples: https://www.proteinatlas.org/ENSG00000164087-POC1A/pathology/liver+cancer#img . Scale bar: 100 µm. (K) Analysis of POC1A mRNA expression in LO2 and HepG2 cell lines by qPCR assay. *, P<0.05; **, P<0.01; -: no significance. TCGA, The Cancer Genome Atlas; HCC, hepatocellular carcinoma; LIHC, liver hepatocellular carcinoma; mRNA, messenger RNA; qPCR, quantitative polymerase chain reaction; POC1A , POC1 centriolar protein A.

Article Snippet: The human normal hepatocyte cell line LO2 (Servicebio Technology Co., Ltd., Wuhan, China) was cultured in Roswell Park Memorial Institute 1640 medium, and the hepatoma cell line HepG2 (Procell Life Science & Technology Co., Ltd., Wuhan, China) was cultured in Dulbecco’s Modified Eagle Medium (Hyclone, Thermo Fisher Scientific Inc., Waltham, MA), supplemented with 10% fetal bovine serum and antibiotics (10,000 U/mL penicillin and 10 mg/mL streptomycin) (Procell Life Science & Technology Co., Ltd.).

Techniques: Expressing, Comparison, Immunohistochemical staining, Real-time Polymerase Chain Reaction